Geetha Achanta PhD

@teamoncology @UHCancerCenter Congratulations @teamoncology

Our new ADC review from @UHCancerCenter explores the latest mechanisms of resistance in #breastcancer and how to strategically understand and tackle them. #OncoAlert advanced.onlinelibrary.wiley.com/doi/10.1002/ad…

@drgandara @TomVargheseJr @GeiselMed @DartmouthCancer @SWOG @theNCI @DrRoyHerbst Congratulations @DrRoyHerbst

Congratulations to Roy Herbst and equally to Dartmouth Comprehensive Cancer Center! @GeiselMed @DartmouthCancer @SWOG @theNCI @DrRoyHerbst

@montypal @crisbergerot @VincentWenxinXu @alantanmd @DrVaishampayan @DocMattCampbell @OncLive Great panel! Thanks for a great discussion @montypal @DrVaishampayan @DocMattCampbell @alantanmd @VincentWenxinXu

Had a great time discussing current topics in #kidneycancer with @VincentWenxinXu, @alantanmd, @DrVaishampayan & @DocMattCampbell! Lots of discussion around topics salient to #GU26! Thanks @OncLive for the opportunity.

@BRicciutiMD @Nature @HugoAerts @Simon_Bernatz Congratulations @BRicciutiMD

Pleased to share our latest study in @Nature. We identify radiographic thymic health as a tumor-agnostic biomarker, hiding in plain sight, of #ICI outcomes. ⬆️thymic health associates with #ICI efficacy, ⬆️TCR diversity & TRECs. @HugoAerts @Simon_Bernatz nature.com/articles/s4158…

🫁 stage III N2+ (bx proven) operable Phase2 trial just published - CHIO3 ➡️multicenter trial 4 cycles neo-adj chemo + Durva ➡️N2 clearance 73% ➡️pCR 30%, mPR 50% ➡️93% R0 resections 🔪 ➡️93% lobectomy, 7% pneumonectomy ➡️0% mortality at 30 & 90d ✅surgery is feasible and should be considered in N2 🫁 cancer @tssmn @lcsmchat @STS_CTsurgery @GenThorSurgClub @LungCancerEu @IASLC @UVASurgery @UVACancerCenter @AmLungCSI @AstraZenecaUS @ests_womenThor @WomenInThoracic @thoracic ars.els-cdn.com/content/image/… sciencedirect.com/science/articl…

Excited pathologist: there! Do you see the tumefactive necrosis of the perivascular epithelium? That is just a classic spindleoid rosette, a truly textbook example of Zuckerkandl’s sign Me <squinting at the slide in a hopefully convincing manner>:

@marklewismd This is the best! 😀😀

@drjgauthier @Mohty_EBMT qui est Parisien @TheIACH

C’est la journée de la francophonie aujourd’hui! 🇫🇷 Qui parle français par ici? 🤔

@Latinamd @worldbaseballcl Congratulations! What an achievement!!

Congratulations to 🇻🇪 Venezuela winning against all odds the 2026 World Baseball Classic @worldbaseballcl against USA 🇺🇸 3-2 -What a great ending! players in tears, crowd went wild! .. (missing my dad in heaven who would have called me right after this game to celebrate the power of Latinos in sports)

@RahulBanerjeeMD Noooo! How could they? ☹️

That feeling when the clinic rooms are stocked with these helpful laminated diagrams! … but my entire career with plasma cell disorders is missing from it 😂

@PTarantinoMD Beautiful views! So jealous!! 😀

Yet good for boosting creativity Science is partly inspiration, partly execution Inspiration thrives when escaping routine: through beauty, art, nature, or meaningful connections. Execution, instead, demands rigor and tranquillity. Key is to mix both. x.com/ptarantinomd/s…

Fantastic panel at #NYGU on radioligand, immunotherapy, targets and future #prostatecancer therapy. Combinations hold promise but need rational, scientifically informed trials and cooperation across industry partners

Asthenia in cancer care is underrecognized, yet it profoundly impacts patient function, cognition, and quality of life. 🩺 Oncology professionals: Please take 4–5 minutes to share your experience. Help us uncover the hidden burden and improve care. 🔗 forms.gle/ejSpxfuPis3afV…

@StephenVLiu @PatelOncology @benlevylungdoc Great picture of the Three “superstar” Amigos!

Ready for some spirted discussion on the current best approaches to treating lung cancer at the “Summit at the Summit” in Utah with @benlevylungdoc and @PatelOncology.

In mBC, not all imaging changes mean your therapy has stopped working and switching too early is a real risk. 1/ RECIST 1.1 sets a clear bar for progression: ≥20% increase in the sum of target lesion diameters (with ≥5mm absolute increase), unequivocal progression of non-target lesions, or new lesions. Not every change on imaging meets this threshold. 2/ Three scenarios commonly and incorrectly flagged as progression: new asymptomatic sclerotic bone lesions, small mm asymptomatic changes in known lesions, and increased SUV on PET without corresponding size change. None of these, in isolation, trigger a therapy switch for me. 3/ Sclerotic bone lesions deserve particular attention. When effective therapy kills tumor cells in bone, the body lays down new bone matrix appearing dense and white on CT. This is a healing response, not new disease. 4/ The consequences of switching too early are real: loss of disease control from a working regimen, premature exhaustion of sequencing options. 5/ My approach: I integrate clinical symptoms, tumor markers, and serial scans together before making any decision to change therapy. 6/ Bottom line: confirm true progression before changing course. When in doubt, a short interval rescan is almost always preferable to an unnecessary switch. #BreastCancer #MedOnc

More scenes from the Miami Breast Cancer Conference #MBCC2026

@CancerNetwrk @Neil_Iyengar Thank you @Neil_Iyengar for all your support at Miami Breast! Don’t know how you manage to be everywhere and do it all but we are so grateful for you!!

👨‍⚕️@Neil_Iyengar is at Miami Breast speaking with attendees about ONCOLOGY. 🤔Interested in submitting? Learn more here cancernetwork.com/oncology-journ…

@PGrivasMDPhD @RahulBanerjeeMD @fredhutch @gotoPER @mshadman @VenurVyshak @HutchPresident Thank you for sharing @PGrivasMDPhD Excited for the great speaker lineup for this meeting! @mshadman @RahulBanerjeeMD @fredhutch @gotoPER @MJHLifeSciences

@fredhutch @gotoPER @mshadman @RahulBanerjeeMD @VenurVyshak @HutchPresident

Congratulations @curijoey What a great honor!